Theratechnologies Inc banner

Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89%
Market Cap: CA$205.5m

Theratechnologies Inc
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Theratechnologies Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Other
-$5m
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Other
-CA$360.1k
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
e
enGene Holdings Inc
NASDAQ:ENGN
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
205.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.07 CAD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Other?
Other
-5m USD

Based on the financial report for May 31, 2025, Theratechnologies Inc's Other amounts to -5m USD.

What is Theratechnologies Inc's Other growth rate?
Other CAGR 5Y
-8%

Over the last year, the Other growth was -67%. The average annual Other growth rates for Theratechnologies Inc have been -8% over the past three years , -8% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett